Oncolytics Biotech (ONCY) Competitors $1.08 +0.14 (+14.86%) Closing price 04:00 PM EasternExtended Trading$1.04 -0.04 (-3.24%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY vs. ARCT, CRVS, ABEO, OLMA, ALDX, AMRN, BNTC, RCKT, INBX, and NGNEShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Arcturus Therapeutics (ARCT), Corvus Pharmaceuticals (CRVS), Abeona Therapeutics (ABEO), Olema Pharmaceuticals (OLMA), Aldeyra Therapeutics (ALDX), Amarin (AMRN), Benitec Biopharma (BNTC), Rocket Pharmaceuticals (RCKT), Inhibrx Biosciences (INBX), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Its Competitors Arcturus Therapeutics Corvus Pharmaceuticals Abeona Therapeutics Olema Pharmaceuticals Aldeyra Therapeutics Amarin Benitec Biopharma Rocket Pharmaceuticals Inhibrx Biosciences Neurogene Oncolytics Biotech (NASDAQ:ONCY) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do institutionals & insiders hold more shares of ONCY or ARCT? 6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, ONCY or ARCT? Oncolytics Biotech has higher earnings, but lower revenue than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-$23.14M-$0.27-4.00Arcturus Therapeutics$152.31M3.47-$80.94M-$2.23-8.74 Is ONCY or ARCT more profitable? Oncolytics Biotech has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -49.26%. Arcturus Therapeutics' return on equity of -24.87% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -438.11% -143.90% Arcturus Therapeutics -49.26%-24.87%-17.75% Do analysts prefer ONCY or ARCT? Oncolytics Biotech presently has a consensus price target of $5.00, suggesting a potential upside of 362.96%. Arcturus Therapeutics has a consensus price target of $50.00, suggesting a potential upside of 156.67%. Given Oncolytics Biotech's higher probable upside, research analysts plainly believe Oncolytics Biotech is more favorable than Arcturus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, ONCY or ARCT? Oncolytics Biotech has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Does the media prefer ONCY or ARCT? In the previous week, Arcturus Therapeutics had 22 more articles in the media than Oncolytics Biotech. MarketBeat recorded 30 mentions for Arcturus Therapeutics and 8 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.51 beat Arcturus Therapeutics' score of 0.45 indicating that Oncolytics Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 0 Very Positive mention(s) 6 Positive mention(s) 13 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryArcturus Therapeutics beats Oncolytics Biotech on 9 of the 15 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.20M$3.13B$5.68B$9.80BDividend YieldN/A2.23%4.59%4.07%P/E Ratio-4.0020.7930.6825.54Price / SalesN/A371.51463.80116.04Price / CashN/A43.0338.2159.48Price / Book21.608.638.996.13Net Income-$23.14M-$54.65M$3.25B$264.89M7 Day Performance25.82%6.59%4.76%2.66%1 Month Performance-4.42%9.57%6.72%3.05%1 Year Performance11.33%14.06%30.51%25.05% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech1.8609 of 5 stars$1.08+14.9%$5.00+363.0%-4.1%$105.20MN/A-4.0030Earnings ReportAnalyst ForecastARCTArcturus Therapeutics2.8717 of 5 stars$11.39-4.4%$54.00+374.1%+0.1%$323.01M$152.31M-4.50180Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeCRVSCorvus Pharmaceuticals2.9062 of 5 stars$4.37+1.4%$15.00+243.2%+39.0%$321.15MN/A-4.3330News CoverageAnalyst RevisionABEOAbeona Therapeutics4.1532 of 5 stars$6.28+0.3%$19.25+206.5%+46.1%$320.24M$3.50M-4.9490Trending NewsEarnings ReportAnalyst ForecastOLMAOlema Pharmaceuticals1.6467 of 5 stars$4.57-1.5%$24.50+436.1%-56.2%$317.48MN/A0.0070News CoverageEarnings ReportAnalyst ForecastALDXAldeyra Therapeutics2.0724 of 5 stars$5.25-0.2%$9.50+81.0%+13.0%$315.05MN/A-6.1810News CoverageInsider TradeAnalyst RevisionAMRNAmarin0.2067 of 5 stars$14.94-0.3%$12.00-19.7%+23.0%$310.40M$228.61M-4.07360BNTCBenitec Biopharma1.7513 of 5 stars$11.90+0.8%$26.00+118.5%+45.0%$309.76M$80K-7.8820News CoveragePositive NewsRCKTRocket Pharmaceuticals4.8432 of 5 stars$2.92+2.1%$16.33+459.4%-83.4%$308.61MN/A-1.16240Analyst RevisionGap UpINBXInhibrx Biosciences1.9705 of 5 stars$21.40+1.6%N/A+112.0%$304.86M$200K0.18166News CoverageEarnings ReportShort Interest ↓NGNENeurogene1.9859 of 5 stars$20.35-4.1%$46.17+126.9%-39.8%$302.64M$930K0.0090News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies Arcturus Therapeutics Competitors Corvus Pharmaceuticals Competitors Abeona Therapeutics Competitors Olema Pharmaceuticals Competitors Aldeyra Therapeutics Competitors Amarin Competitors Benitec Biopharma Competitors Rocket Pharmaceuticals Competitors Inhibrx Biosciences Competitors Neurogene Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONCY) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access